A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients  by Floege, Jürgen et al.
OPEN
see commentary on page 471
A phase III study of the efficacy and safety of a novel
iron-based phosphate binder in dialysis patients
Ju¨rgen Floege1, Adrian C. Covic2, Markus Ketteler3, Anjay Rastogi4, Edward M.F. Chong5, Sylvain Gaillard5,
Laura J. Lisk5 and Stuart M. Sprague6, on behalf of the PA21 Study Group
1Division of Nephrology, RWTH University Hospital Aachen, Aachen, Germany; 2‘Grigore T Popa’ University of Medicine and Pharmacy,
Iasi, Romania; 3Coburg Clinic and KfH-Dialysis Center, Coburg, Germany; 4University of California, Los Angeles, California, USA; 5Vifor
Pharma, Glattbrugg, Switzerland and 6NorthShore University Health System University of Chicago Pritzker School of Medicine, Evanston,
Illinois, USA
Efficacy of PA21 (sucroferric oxyhydroxide), a novel calcium-
free polynuclear iron(III)-oxyhydroxide phosphate binder,
was compared with that of sevelamer carbonate in an
open-label, randomized, active-controlled phase III study.
Seven hundred and seven hemo- and peritoneal dialysis
patients with hyperphosphatemia received PA21 1.0–3.0 g
per day and 348 received sevelamer 4.8–14.4g per day for an
8-week dose titration, followed by 4 weeks without dose
change, and then 12 weeks maintenance. Serum phosphorus
reductions at week 12 were  0.71mmol/l (PA21) and
 0.79mmol/l (sevelamer), demonstrating non-inferiority of,
on average, three tablets of PA21 vs. eight of sevelamer.
Efficacy was maintained to week 24. Non-adherence was
15.1% (PA21) vs. 21.3% (sevelamer). The percentage of
patients that reported at least one treatment-emergent
adverse event was 83.2% with PA21 and 76.1% with
sevelamer. A higher proportion of patients withdrew owing
to treatment-emergent adverse events with PA21 (15.7%) vs.
sevelamer (6.6%). Mild, transient diarrhea, discolored feces,
and hyperphosphatemia were more frequent with PA21;
nausea and constipation were more frequent with sevelamer.
After 24 weeks, 99 hemodialysis patients on PA21 were
re-randomized into a 3-week superiority analysis of PA21
maintenance dose in 50 patients vs. low dose (250mg per
day (ineffective control)) in 49 patients. The PA21
maintenance dose was superior to the low dose in
maintaining serum phosphorus control. Thus, PA21 was
effective in lowering serum phosphorus in dialysis patients,
with similar efficacy to sevelamer carbonate, a lower pill
burden, and better adherence.
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Hyperphosphatemia is an almost inevitable consequence of
chronic kidney disease, particularly in its advanced stages. In
chronic kidney disease patients, the inability to maintain
phosphorus balance is central to the development of chronic
kidney disease-mineral and bone disorder1 and is associated
with increased cardiovascular events2 and increased mortality.3–6
Most patients on dialysis require phosphate binders to control
hyperphosphatemia. Treatment with phosphate binders has
been associated with a survival benefit.7,8 However, most phos-
phate binders are associated with a high pill burden, posing a
major obstacle to adherence for patients attempting to maintain
optimal control of serum phosphorus concentrations.9,10
A phosphate binder with a low pill burden and good
tolerability may improve adherence and could thereby help
optimize serum phosphorus control in patients on dialysis.11
PA21 (sucroferric oxyhydroxide) is a new calcium-free
polynuclear iron(III)-oxyhydroxide phosphate binder with a
high phosphate binding capacity over a wide pH range.12 It is
formulated as flavored, chewable tablets that disintegrate
easily in the gastrointestinal (GI) tract, bind phosphate across
the whole physiologically relevant pH range, each contain
500mg of iron, and may be taken without water.
Phase I studies demonstrated that PA21 was well tolerated
and that GI iron absorption was minimal.12,13 A phase II dose-
finding study demonstrated that PA21 doses of 1.0 2.5 g per
day (based on iron content) were well tolerated and signifi-
cantly lowered serum phosphorus concentrations from
baseline, with maximal effects observed at 2.0–2.5 g per day
(Po0.001). A low dose (LD) of PA21 (250mg per day) was
found to be ineffective.14
In this phase III study, the efficacy and safety of PA21
was compared with that of sevelamer carbonate (SEV) in
treating hyperphosphatemia in patients undergoing dialysis
(Figure 1).
RESULTS
Analysis sets and patient disposition
Overall, 1059 patients were randomized in this study. Of
these, four did not receive treatment (Figure 2). Hence, 1055
patients were included in the safety set (SS). Of those 1055,
c l in i ca l t r i a l http://www.kidney-international.org
& 2014 International Society of Nephrology
Correspondence: Ju¨rgen Floege, Division of Nephrology, RWTH University
Hospital Aachen, 52057 Aachen, Germany.
E-mail: juergen.floege@rwth-aachen.de
Received 12 June 2013; revised 23 December 2013; accepted 2 January
2014; published online 19 March 2014
638 Kidney International (2014) 86, 638–647
1041 patients were included in the full analysis set (FAS),
defined as patients randomized to treatment who received at
least one dose of study medication and had at least one
postbaseline evaluable efficacy assessment. The per-protocol
set (PPS; n¼ 685) consisted of patients who, in addition to
the FAS criteria, had completed the treatment from baseline
to week 12 and had at least one evaluable serum phosphorus
result at or after week 12, with no major protocol deviations.
Patient disposition (stage 1) is shown in Figure 2. Reasons
for patients failing screening were: entry criteria not met
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Figure 1 | Study design.
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N =1840
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PA21
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Sevelamer
carbonate
N =349
Not treated
N =3 (0.4%)
Treated
N =707 (99.6%)
Not treated
N =1 (0.3%)
Treated
N =348 (99.7%)
Withdrawn
N =195/710
(27.5%) 
Completed
N =515/710
(72.5%) 
Withdrawn
N =56/349
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Completed
N =293/349
(84.0%) 
Reasons for withdrawal
(% in relation to number of withdrawals)*:
• Death: 9 (4.6%)
• AE other than serum P or Ca level: 94 (48.2%)
• Hyperphosphatemia: 12 (6.2%)
• Withdrawn consent: 32 (16.4%)
• Investigator or sponsor decision: 10 (5.1%)
• Renal transplant: 16 (8.2%)
• Other: 22 (11.3%)
Reasons for withdrawal
(% in relation to number of withdrawals)*:
• Death: 5 (8.9%)
• AE other than serum P or Ca level: 21 (37.5%)
• Hyperphosphatemia: 0 (0.0%)
• Withdrawn consent: 15 (26.8%)
• Investigator or sponsor decision: 5 (8.9%)
• Renal transplant: 7 (12.5%)
• Other: 3 (5.4%)
*Several reasons for withdrawal were possible in a single patient.
Figure 2 | Patient disposition, stage 1.
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(other than serum phosphorus concentration; 39.1%), serum
phosphorus concentration o1.94mmol/l (34.3%), with-
drawal of consent (6.4%), investigator decision (1.8%), death
during screening/washout (0.3%), and other (18.4%).
Patient baseline demographics (stage 1) are given in
Table 1. Treatment groups were largely similar with regard to
baseline characteristics, with no major differences between
demographic subgroups. Across both treatment groups, 92%
of patients were undergoing HD.
The most common major protocol deviations were non-
adherence to study treatment (19.5%), treatment duration
p11 weeks (13.2%), and use of any phosphate binders
during washout or use of non-study phosphate binders
between baseline and week 12 (5.6%).
Adherence from baseline to week 24 was 82.6% in the
PA21 treatment group and 77.2% in the SEV treatment
group. Furthermore, data suggest that non-adherence to
study treatment (defined as taking o70% of the expected
number of tablets) was more common in patients receiving
SEV compared with PA21 (21.3% vs. 15.1%, respectively). No
differences in diet between the PA21 and SEV treatment
groups were observed.
Overall, 27.5% of patients receiving PA21 and 16.0% of
those receiving SEV were withdrawn prematurely from the
study. The most common reasons for study withdrawal (all
patients) were adverse events (AEs) other than phosphorus or
calcium concentrations (45.8%), and withdrawn consent
(18.7%) (Figure 2). Mean (s.d.) prewashout serum phos-
phorus concentrations in the FAS were 1.99mmol/l (0.558)
in the PA21 group (N¼ 694) and 1.96mmol/l (0.521) in the
SEV group (N¼ 347).
Efficacy
Non-inferiority of PA21 versus SEV was demonstrated: the
upper bound of the 97.5% one-sided confidence interval of
the least-squares mean difference in change from baseline to
week 12 in serum phosphorus was 0.15mmol/l, which was
below the predefined non-inferiority margin of 0.19mmol/l
(Supplementary Data and Table S2 online). Mean changes in
serum phosphorus concentrations from baseline to week 12
were  0.71mmol/l in the PA21 group and  0.79mmol/l in
the SEV group. Results of the non-inferiority analysis in the
FAS were consistent with PPS results: the upper bound of the
97.5% one-sided confidence interval of the least-squares
mean difference in change from baseline to week 12 in serum
phosphorus was 0.16mmol/l, which was also below the
predefined non-inferiority margin. There were no significant
interactions of demographic and disease covariates (includ-
ing the type of dialysis) with treatment effects.
Patients taking PA21 and SEV initiated treatment on two
and six tablets per day, respectively; in the FAS, mean baseline
phosphorus values were 2.5 and 2.4mmol/l, respectively
(Figure 3). Rapid reductions in mean serum phosphorus
were seen in both treatment groups and were maintained to
the week 24 end point (Figure 3).
Table 1 | Baseline demographics, Stage 1 (FAS; N¼ 1041)
Parameter PA21 Sevelamer Total
N (%) 694 (100%)347 (100%)1041 (100%)
Mean (s.d.) age (years) 56 (13) 56 (15) 56 (14)
Male (%) 55.2 63.1 57.8
Race
White (%) 77.2 75.8 76.8
Black/African American (%) 18.3 21.6 19.4
Other (%) 4.5 2.6 3.8
Ethnicity
Hispanic/Latino (%) 12.7 11.0 12.1
Non-Hispanic/Latino (%) 87.3 89.0 87.9
Mean (s.d.) weight (kg) 83 (21) 84 (21) 83 (21)
Reason for end-stage renal disease
Hypertension (%) 22.8 25.4 23.6
Glomerulonephritis (%) 22.3 25.1 23.2
Diabetic nephropathy (%) 28.2 27.1 27.9
Other (%) 26.7 22.5 25.3
Dialysis modality
Hemodialysis (%) 91.9 91.6 91.8
Peritoneal (%) 8.1 8.4 8.2
Mean (s.d.) time from first dialysis
(months)
51 (49) 54 (55) 52 (51)
Prior phosphate binders
Calcium-based (%) 65.6 64.8 65.3
Aluminum-based (%) 3.0 4.0 3.4
Lanthanum (%) 6.5 4.0 5.7
Sevelamer (%) 34.3 35.7 34.8
Any time in previous 12 months (%) 37.3 39.5 38.0
Other (%) 1.3 0.9 1.2
Abbreviations: FAS, full analysis set; PA21, sucroferric oxyhydroxide.
Table 2 | Overall TEAEs and TEAEs occurring in X5% of
patients in either treatment group, stage 1 (SS; N¼ 1055)
PA21
(N¼ 707) (%)
Sevelamer
(N¼ 348) (%)
Any TEAE 83.2 76.1
Any severe TEAE 11.5 10.9
Any serious TEAE 18.2 19.8
Withdrawals due to TEAEs 15.7 6.6
Death 1.8 2.0
Any GI TEAE 45.1 33.6
Any GI TEAE, excluding isolated
discolored feces
39.0 33.3
Diarrhea 20.1 7.5
Feces discolored 15.4 0.3
Hyperphosphatemia 11.2 7.8
Nausea 7.2 11.2
Hypertension 6.4 7.5
Vomiting 4.4 5.5
Constipation 3.8 7.2
Abbreviations: GI, gastrointestinal; PA21, sucroferric oxyhydroxide; SS, safety set;
TEAE, treatment-emergent adverse event.
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For the first 12 weeks, mean pill burden in the PA21 and
SEV treatment groups was 2.8 and 7.6 tablets per day,
respectively. The mean pill burden in the maintenance phase
was 3.6 tablets per day for PA21 and 8.7 tablets per day for
SEV (Figure 4). The pill burden remained greater with SEV
than with PA21 over the whole course of the study, and the
overall mean number of tablets taken per day from baseline
to week 24 being 3.1 for PA21 and 8.1 for SEV.
At week 24, mean serum phosphorus concentrations in
the primary efficacy set were similar in both treatment
groups: 1.5mmol/l in the maintenance dose (MD) group
(n¼ 50) and 1.6mmol/l in the LD group (n¼ 49; Figure 5).
In the MD group, mean serum phosphorus concentrations
did not change significantly from weeks 24 to 27. However,
in the LD group mean values increased by 0.6mmol/l,
which was significantly higher than that in the MD
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group (Po0.001), thereby demonstrating superiority of the
MD group. There were no significant interactions of
demographic and disease covariates with treatment effects.
Similar results were obtained for the primary efficacy per-
protocol set.
Median serum intact parathyroid hormone concentrations
decreased significantly from baseline to week 24 in both
treatment groups; the decrease was more pronounced in
the PA21 group (P¼ 0.0400 for the comparison of changes
between groups; Supplementary Data Table S1 online).
Median serum concentrations of 25(OH)D decreased from
baseline to week 24 in both treatment groups (Supplemen-
tary Data and Table S1 online). This change from baseline to
week 24 was statistically significant in both treatment groups,
with the decrease being more pronounced with SEV
(P¼ 0.0190 for the comparison of changes between groups).
Median serum concentrations of 1,25(OH)2D remained
unchanged from baseline to week 24 in the PA21 group,
but decreased significantly from baseline to week 24 in the
SEV group (P¼ 0.0316 for the comparison of changes
between groups).
Safety
The percentage of patients that reported at least one
treatment-emergent AE (TEAE) was higher with PA21
(83.2%) than with SEV (76.1%). TEAEs reported more
frequently with PA21 were diarrhea (PA21, 20.1%; SEV,
7.5%), discolored stools (PA21, 15.4%; SEV, 0.3%), and
hyperphosphatemia (PA21, 11.2%; SEV, 7.8%), whereas
constipation (PA21, 3.8%; SEV, 7.2%) and nausea (PA21,
7.2%; SEV, 11.2%) were reported more frequently with SEV,
over 24 weeks in stage 1 (Table 2). Incidences of severe and
serious TEAEs and deaths were similar between PA21 and
SEV treatment groups.
Few severe (PA21, 1.0%; SEV, 1.1%) or serious TEAEs
(PA21, 0.3%; SEV, 0.0%) were considered related to study
treatment by the investigator (data not shown). One patient
treated with PA21 was hospitalized for evaluation of dis-
colored feces, which was therefore classified as serious per
definition. PA21 was not discontinued and the condition was
reported as recovered without sequelae. One patient in the
PA21 treatment group developed a duodenal ulcer with GI
bleeding, classified as serious and treatment-related, which was
later resolved. No fatal TEAEs were related to study treatment.
Reported deaths were mostly related to cardiac disorders.
A higher incidence of TEAEs leading to withdrawal was
observed with PA21 (15.7% and 6.6% for PA21 and SEV,
respectively). In both treatment groups, GI events accounted
for large proportions of the TEAEs leading to withdrawal
(54.0% and 43.5%, respectively). The most frequent AEs
leading to withdrawal are shown in Table 3. Of note, 1.4% of
patients in the PA21 group withdrew because of hyperphos-
phatemia, compared with none in the SEV group. Although
not requiring withdrawal, over the course of the study, 9.9%
of patients received PA21, and 12.9% of patients taking SEV
required X1 dose adjustment for tolerability.
The most frequent TEAEs were GI in nature. The overall
incidence of GI TEAEs was higher with PA21 (45.1% vs.
33.6% with SEV; Table 2). Excluding isolated cases of dis-
colored feces, the incidence of GI TEAEs was 39.0% in the
PA21 group and 33.3% in the SEV group. A higher propor-
tion of treatment-related TEAEs was reported in the PA21
group (39.6% vs. 19.8% in the SEV group). These differences
between treatment groups were largely driven by higher
incidences of discolored feces and diarrhea. All cases of
discolored feces associated with PA21 were reported during
the titration phase and rarely led to withdrawal (0.7%).
Diarrhea generally presented early in treatment (Figure 6),
and resolved without the need for specific therapies or
treatment changes. The proportions of patients experiencing
diarrhea were higher during the titration phase compared
with the maintenance phase for both PA21 (17.3% vs. 5.5%)
and SEV (6.0% vs. 2.3%). Most cases of diarrhea were mild in
both the PA21 (69%) and SEV (58%) groups. Diarrhea led to
withdrawal in 2.8% of patients receiving PA21 (mainly in the
titration phase) and in 0.6% of those receiving SEV.
Iron parameters are shown in Figure 7. There were no
significant changes in hemoglobin parameters. Median serum
Table 3 | TEAEs that led to study withdrawal in X1.0% of
patients in either treatment group, stage 1 (SS; N¼ 1055)
PA21 (N¼ 707) (%) Sevelamer (N¼ 348) (%)
Any TEAE 15.7 6.6
Diarrhea 2.8 0.6
Nausea 1.6 0.6
Abnormal product taste 1.6 0.3
Hyperphosphatemia 1.4 0.0
Constipation 1.0 1.4
Vomiting 1.0 0.6
Abbreviations: AE, adverse event; PA21, sucroferric oxyhydroxide; SS, safety set;
TEAE, treatment-emergent AE.
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ferritin concentrations increased in both treatment groups.
Increases in transferrin saturation were only seen with PA21.
Iron parameters are also shown by region (Supplementary
Data and Figure S1 online). In the overall population, 470
and 480% of patients received concomitant intravenous
iron products and erythropoiesis-stimulating agents, respec-
tively, during the study. Specifically, 70.6% of patients in the
PA21 group and 74.1% of patients in the SEV group received
concomitant iron products during stage 1. Use of intravenous
iron products varied by region: it was 72.5% in the United
States, 53.4% in Europe, and 33.3% in all remaining
countries in the study.
Median serum concentrations of C-reactive protein did
not change from baseline to week 24 in the PA21 group and
decreased by 0.10mg/l in the SEV group (P¼ 0.0270 for the
comparison of changes between groups; Supplementary Data
and Table S1 online).
DISCUSSION
PA21 was found to be non-inferior to SEV, as reductions in
serum phosphorus concentrations were similar (0.71 and
0.79mmol/l over the first 12 weeks of treatment, respec-
tively), and maintained its phosphorus-lowering effect over
24 weeks with a considerably lower pill burden than SEV. In
addition, treatment for 3 weeks with PA21 MD was superior
to PA21 LD in maintaining serum phosphorus control after
24 weeks of treatment. Both primary and secondary efficacy
objectives were met, demonstrating that PA21 is effective for
the control of hyperphosphatemia in dialysis patients.
Patients undergoing dialysis often have multiple comorbid
conditions and subsequently face a high pill burden, with one
study showing a median of 19 tablets per day and some
dialysis patients taking 430 tablets per day.10 Phosphate
binders accounted for 49% of this total daily tablet count,
with a median daily pill burden of nine.10 Increased pill
burden has been associated with reduced adherence to
phosphate binders and lower quality of life.10 Non-adherence
to phosphate binders, as high as 62% in patients with end-stage
renal disease,10 has been associated with hyperphospha-
temia,15 thus increasing the risk of secondary hyperparathy-
roidism, renal osteodystrophy, cardiovascular disease, and
mortality.9,16,17 Recently published data from the pharmacy
management program of a large dialysis provider indicate
that phosphate binder pill burden is negatively associated
with medication adherence (defined by the medication pos-
session ratio), which, in turn, is negatively associated with
mean phosphorus concentrations.18 Reducing pill burden,
while maintaining efficacy, may increase adherence of dialysis
patients to phosphate binders and to other medications.
In the current study, patients treated with SEV required on
average 2.6 times more tablets per day than those receiving
PA21 (8.1 vs. 3.1, respectively) to achieve comparable control
of serum phosphorus concentrations over 24 weeks.
Patient-reported side effects have been cited as another
major reason for poor adherence to, or discontinuation of,
phosphate binders.19 As expected in this patient population,
the overall incidence of TEAEs was high in both treatment
groups, although it was higher with PA21 (83.2%) than with
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SEV (76.1%). Incidence of severe or serious TEAEs and
deaths was similar between groups. The higher incidence of
TEAEs with PA21 was largely due to higher incidences of GI
TEAEs, particularly diarrhea (PA21, 20.1%; SEV, 7.5%) and
discolored stools (PA21, 15.4%; SEV, 0.3%). Diarrhea, which
included descriptions such as ‘loose’ or ‘soft’ stools, was
generally mild, transient, early in onset, led to few
withdrawals, and did not require specific treatment in the
PA21 treatment group. Such TEAEs should be considered in
context: more than one in two patients with end-stage renal
disease on dialysis experience constipation.20 Of the reported
GI TEAEs, constipation, nausea, and upper abdominal pain/
discomfort were more common in patients treated with SEV
compared with those receiving PA21. SEV has previously
been reported to be associated with nausea, vomiting,
constipation, and diarrhea.21 Discolored stools have been
commonly reported with PA21, other iron-based phosphate
binders,14,22 and with iron-based products in general.
An increase in ferritin concentrations was observed in
both treatment groups, and an increase in transferrin
saturation was observed in the PA21 group. These increases
occurred early and plateaued on continuing treatment with
PA21, indicating no accumulation of iron. One potential
explanation for the increase in these iron parameters is the
use of intravenous iron in the majority of the study
participants, particularly in patients from the United States,
who accounted for nearly half of all randomized patients: the
implementation of the prospective payment system by the
United States Centers for Medicare and Medicaid Services led
to an increase in intravenous iron use during the time in
which this study was conducted.23 Analysis of iron param-
eters by region (USA, Europe, and Rest of World)
(Supplementary Data and Figure S1 online) is supportive
of this explanation. The higher use of intravenous iron in the
United States (72.5% compared with 53.4% in Europe and
33.3% across all other countries in the study) is associated
with a higher baseline serum ferritin and larger increases in
serum ferritin from baseline to week 24 compared with the
other two regions. However, the larger increases in ferritin
and transferrin saturation in the PA21 treatment group
indicate that it cannot be ruled out that a small amount of
iron can be absorbed from PA21. This would be in line with
data from a phase I study of PA21, in which administration of
a single dose of 2.0 g of radiolabeled PA21 was associated
with minimal iron absorption in chronic kidney disease
patients on dialysis (median 0.02%, range 0–0.04%).12
A more pronounced effect on iron parameters has been
reported with another iron-based phosphate binder, ferric
citrate;24,25 the discrepancy in the effects on iron parameters
between the two agents may be attributable to the difference
between the two compounds, with PA21 being designed to
minimize iron release and absorption.12
Low-dose PA21 was chosen as the control in stage 2
because it was proven to be ineffective in a previous phase II
study14 and, therefore, provides a way of comparing a
placebo-like dose with therapeutic dosing (i.e., PA21 MD).
A limitation of the current study is its open-label design.
However, use of a double-blind study design was not feasible
owing to the differences in formulation and type of admini-
stration between PA21 and SEV. Black stools, as a result of the
PA21 iron content, would also be difficult to mask properly.
Treatment adherence was calculated on the basis of the
number of tablets returned by patients; it is widely acknow-
ledged that this method of assessment has limited accuracy,
and should be interpreted with caution. The starting dose of
PA21 involved two times daily dosing, whereas SEV was taken
three times daily. As such, patients who were having more
than two meals per day and were receiving PA21 two times
daily had at least one meal without a phosphate binder. In
retrospect, the use of two times daily dosing as a starting dose
was not ideal and may have accounted for the 1.4% of
withdrawals due to hyperphosphatemia in the PA21 treat-
ment group that occurred in stage 1 of the study. However, by
weeks 12–24, the mean daily number of tablets in the PA21
group was 3.6 (Figure 4), indicating that most patients in the
PA21 group were receiving a three times daily dosing. Given
this observation, the study sponsor will seek approval for a
three times daily dosing schedule. Finally, it should be noted
that 38% of patients in this study had received treatment with
SEV during the 12 months before study entry. As such, a large
proportion of patients may already have been familiar with
and acclimated to the side effects associated with SEV, which
may have affected the perception and reporting of AEs in this
treatment group.
In conclusion, PA21 had similar efficacy and tolerability to
SEV in dialysis patients, although having a lower pill burden.
Therefore, PA21 may represent a new treatment option for
hemo- (HD) and peritoneal dialysis (PD) patients, with the
potential for improved adherence.
MATERIALS AND METHODS
Study design
This was a multicenter, open-label, two-stage, prospective, rando-
mized, parallel-group, active-controlled study of PA21 compared
with SEV conducted in 174 sites across Europe, the United States,
Russia, Ukraine, and South Africa (Figure 1).
There were two major efficacy objectives: to investigate non-
inferiority of PA21 versus SEV, and superiority of the PA21 MD
versus LD. Stage 1 (baseline to week 24) evaluated changes in serum
phosphorus from baseline in the PA21 and SEV treatment groups:
the efficacy objective was to demonstrate non-inferiority of PA21
versus SEV at week 12. Stage 2 (weeks 24–27) was an open-label,
3-week comparison of PA21 MD versus LD control (fixed dose of
250mg per day) performed only in HD patients previously treated
with PA21. The efficacy objective in stage 2 was to demonstrate
superiority of PA21 MD versus LD.
The protocol was reviewed by Independent Ethics Committees or
Institutional Review Boards, and the study was conducted in
accordance with the Declaration of Helsinki Principles, the Interna-
tional Conference on Harmonisation E6 Guideline for Good Clinical
Practice, Committee for Proprietary Medicinal Products guideline
(CPMP/ICH/135/95), and was compliant with the European Union
Clinical Trial Directive (Directive 2001/20/EC) and the Code of
Federal Regulations for informed consent and protection of patient
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rights. The study is registered as NCT01324128 on the Clinical-
Trials.gov website. Informed consent was obtained before any study-
specific procedures were performed. The first screening visit took
place in March 2011.
Following screening, eligible patients completed a 2–4 week
washout from their previous phosphate binders. Patients with serum
phosphorus concentrationsX1.94mmol/l were then randomized to
treatment via an interactive voice response system (Perceptive
Informatics, Billerica, MA). Patients were randomized in a 2:1 ratio
to receive PA21 1.0–3.0 g per day (2–6 chewable tablets per day) or SEV
4.8–14.4 g per day (6–18 tablets per day). Doses of PA21 are based on
iron content. PA21 chewable tablets are 2 cm (diameter)6mm
(depth). SEV tablets are oval and 19mm in diameter.
Patients receiving PA21 began stage 1 with a dose of 1.0 g per day
(2 chewable tablets per day), and those receiving SEV began with a
dose of 4.8 g per day (6 tablets per day). The daily dose distribution
at the start of the study differed across the two treatment groups: the
starting dose of PA21 was taken two times daily, whereas SEV was
taken three times daily. At the start of the study, patients in the PA21
group were advised to take one PA21 tablet with each of the two
largest meals of the day. ‘Largest meals’ were defined as the meals
with the highest phosphorus content. The study comprised an
8-week dose titration, during which doses of each drug could be
titrated for efficacy or tolerability, followed by 4 weeks during which
dose changes were only permitted for tolerability. A 12-week
maintenance period followed, during which dose titration was
permitted for efficacy and tolerability. The permitted dose titration
for PA21 was 500mg per day (1 tablet) every 2 weeks (minimum
dose, 1.0 g per day (2 tablets); maximum dose, 3.0 g per day
(6 tablets)). For SEV, the permitted dose titration was 2.4 g per day
(3 tablets) every 2 weeks (minimum dose, 2.4 g per day (3 tablets);
maximum dose, 14.4 g per day (18 tablets)). Patients participating in
stage 2 were randomized to receive either the same dose of PA21 that
they had been receiving at the end of stage 1 (week 24) or low-dose
PA21 (250mg per day) for 3 weeks, with no dose adjustments
permitted.
Concomitant medications that have a direct influence on serum
phosphorus concentrations (e.g., vitamin D, vitamin D analogs, and
calcimimetics) remained unchanged as far as possible, in accordance
with local clinical practice. Laboratory testing was performed at
central laboratories, although local laboratories could be used for
the measurement of serum phosphorus concentrations for dose
titration purposes.
Participants
Eligible patients (aged X18 years) had a history of hyperpho-
sphatemia and were treated with stable doses of phosphate binders
for X1 month before screening. Eligible patients also received
maintenance HD three times per week (Kt/V X1.2) or PD (Kt/V
X1.7) for at least 3 months before screening. Patients were also
required to have serum phosphorus concentrations X1.94mmol/l
during the washout period.
Patients were ineligible for the study if they presented with
intact parathyroid hormone concentrations 4800 ng/l (88 pmol/l)
at screening, or if parathyroidectomy was planned or expected.
Patients were also excluded if they had significant GI or hepatic
disorders, or major GI surgery or serum ferritin 44494 pmol/l
(42000mg/l) at screening. Patients on PD with a history of peri-
tonitis in the past 3 months or X3 episodes in the past 12 months
were ineligible. Patients receiving non-calcium-based phosphate
binders with hypercalcemia (total serum calcium 42.60mmol/l),
or patients with hypocalcemia (total serum calcium o1.9mmol/l)
at screening were also excluded. Antacids containing aluminum,
calcium, or magnesium, and oral iron therapies/supplements were
not permitted.
Patients were withdrawn if, despite appropriate interventions,
their serum phosphorus concentrations exceeded the upper safety
limit of 2.75mmol/l or decreased below the lower safety limit of
0.81mmol/l, or total serum calcium concentrations exceeded
2.75mmol/l.
Assessments
Patients on HD had weekly study visits for the first 8 weeks of
treatment, and then every 4 weeks until week 24. Study visits were
planned to coincide with the first dialysis session of the week.
Collection of laboratory samples was completed before dialysis, that
is, serum phosphorus was measured predialysis. Patients on PD had
study visits every second week for the first 8 weeks of treatment, and
then every 4 weeks until week 24. All subsequent study visits were
scheduled on the same day thereafter (±1 day).
In both HD and PD patients, AEs and concomitant medications
were recorded from screening (informed consent signature) to the
end of study participation.
Per-protocol, hyperphosphatemia was defined as serum phosphorus
42.75mmol/l, hypophosphatemia as serum phosphorus o0.81
mmol/l, and hypercalcemia as total serum calcium 42.75mmol/l,
despite appropriate dose adjustments or interventions. Patients had
to be withdrawn when these limits were exceeded.
Treatment adherence was calculated on the basis of the number
of tablets returned by patients:
total actual number of tablets taken during a period
number of tablets expected to be taken during a period
 100 %
Sample size calculations and statistics
The primary efficacy end point was an analysis of the superiority of
PA21 MD versus LD in maintaining the phosphorus lowering effect
in patients undergoing HD, by assessing serum phosphorus from
weeks 24 to 27 (stage 2; Figure 1). The key secondary efficacy end
point was an analysis of the non-inferiority of PA21 compared with
SEV in lowering serum phosphorus in patients on dialysis, by
assessing change in serum phosphorus from baseline to week 12
(stage 1). The safety end points were AEs and routine biochemical
and hematologic laboratory parameter changes from baseline.
The study sample size was determined by the non-inferiority
comparison between PA21 and SEV, with the following assumptions:
a mean decrease in serum phosphorus concentrations of 0.65mmol/l
in both treatment groups, with a standard deviation of 0.63mmol/l,
a power of 90%, a non-inferiority margin of 0.19mmol/l, and a
randomization ratio of 2:1 (PA21:SEV). A total of 507 per-protocol
patients was required. To account for a 20% rate of patients being
excluded from the per-protocol group, a minimum of 636 patients
was required. Sample size was then increased to 940 patients to
ensure sufficient numbers to meet regulatory requirements for long-
term safety. The sample size for stage 2 of the study was based on the
primary efficacy end point. The number of patients needed for this
analysis was 50 per group, assuming a difference in serum phos-
phorus concentrations of 0.42mmol/l between groups, a standard
deviation of 0.63mmol/l, a power of 90%, and a two-sided
significance value of 0.05.
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The study analyses involved various patient populations. The
FAS comprised patients randomized to treatment who received X1
dose of study medication and had at least one post-baseline
evaluable efficacy assessment. The PPS consisted of patients who, in
addition to the FAS criteria, had completed the treatment course
from baseline to week 12, had at least one evaluable serum
phosphorus result at or after week 12, and had no major protocol
deviations. The SS comprised all randomized patients who took at
least one dose of study medication. The primary efficacy set
comprised patients who were randomized to stage 2, received X1
dose of study medication during stage 2 and had X1 evaluable
postbaseline efficacy assessment during stage 2. The primary efficacy
per-protocol set comprised patients who were randomized to stage 2
and had no major protocol deviations.
The secondary non-inferiority efficacy analysis was conducted on
the PPS and the FAS using an analysis of covariance, and the last
observation carried forward approach of missing data imputation,
with the baseline serum phosphorus concentration, dialysis modality
(HD or PD), and geographical regions (USA, Europe, and other
countries) as covariates. The primary efficacy analysis was also assessed
using an analysis of covariance, with week 24 serum phosphorus
concentration and region as covariates for the primary efficacy set
and primary efficacy per-protocol set. Analysis of covariance for the
primary efficacy end point used the last observation carried forward
approach. In addition, other covariates such as sex, age, race, ethnicity,
time from first dialysis, reason for end-stage renal disease, number
of prior phosphate binders, prior use of SEV (for the non-inferiority
analysis only), and the interactions between these covariates and
treatment were investigated in separate models. The interactions
were tested at a level of 0.10. Summary statistics were used to
analyze safety data from the SS.
Overall adherence, based on the number of tablets taken relative
to the number expected to be taken, was summarized using
descriptive statistics. Patients were recorded as being adherent if
their adherence was within 70–120% of the expected tablet intake.
Unless otherwise stated, all statistical tests on efficacy data were
performed using two-sided tests at the 5% significance level. The
analyses were conducted using SASs version 9.2 or later (SAS
Institute, Cary, NC). Differences in demographic and adherence
data and AE reporting described in the text were not tested for
statistical significance and are descriptive only.
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